Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pesch

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast CancersAndrea M Pesch, Nicole H Hirsh, Benjamin C Chandler, et al.
Molecular Cancer Therapeutics|August 16, 2019
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing RadiationAnna R Michmerhuizen, Andrea M Pesch, Leah Moubadder, et al.
Cancer Research Communications|November 16, 2022
Bcl-xL inhibition radiosensitizes <i>PIK3CA/PTEN</i> wild-type triple negative breast cancers with low Mcl-1 expressionAndrea M Pesch, Benjamin C Chandler, Anna R Michmerhuizen, et al.
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Frontiers in Endocrinology|March 3, 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer CellsAnna R Michmerhuizen, Benjamin Chandler, Eric Olsen, et al.
NPJ Breast Cancer|March 11, 2022
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
NPJ Breast Cancer|April 21, 2022
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
NPJ Breast Cancer|February 24, 2026
Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibitionBreanna McBean, Benjamin Hauk, Anna R Michmerhuizen, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast CancersAndrea M Pesch, Nicole H Hirsh, Benjamin C Chandler, et al.
Molecular Cancer Therapeutics|August 16, 2019
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing RadiationAnna R Michmerhuizen, Andrea M Pesch, Leah Moubadder, et al.
Cancer Research Communications|November 16, 2022
Bcl-xL inhibition radiosensitizes <i>PIK3CA/PTEN</i> wild-type triple negative breast cancers with low Mcl-1 expressionAndrea M Pesch, Benjamin C Chandler, Anna R Michmerhuizen, et al.
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Frontiers in Endocrinology|March 3, 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer CellsAnna R Michmerhuizen, Benjamin Chandler, Eric Olsen, et al.
NPJ Breast Cancer|March 11, 2022
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
NPJ Breast Cancer|April 21, 2022
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
NPJ Breast Cancer|February 24, 2026
Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibitionBreanna McBean, Benjamin Hauk, Anna R Michmerhuizen, et al.
Pageof 3